Friday 22 November 2024

BRIEF—GSK terminates deal with Immatics

Biotechnology
21 November 2022

More on this story...

Biotechnology
US FDA mulls broader Jemperli label under Priority Review
25 April 2024
Biotechnology
Tagrisso tops triple-dose of AstraZeneca ASCO data
3 June 2024
Biotechnology
BRIEF—Mersana and Merck call halt to Dolaflexin accord
2 January 2024
Biotechnology
Medigene and BioNTech extend TCR immunotherapy collab
21 May 2024


Companies featured in this story

More ones to watch >


Today's issue

Alloy and Takeda team up on CAR-T cell platform
Biotechnology
Alloy and Takeda team up on CAR-T cell platform
21 November 2024
Pharmaceutical
Eisai announces launch of Rozebalamin and Tasfygo
21 November 2024
Pharmaceutical
Merck: a relentless pursuit of the best outcomes for the entire MS community
21 November 2024
Biotechnology
Cidara to raise up to $105 million in private placement
21 November 2024
Pharmaceutical
Novartis upgrades mid-term guidance; buys Kate Thera
21 November 2024
Biotechnology
FDA approves Jazz’s Ziihera for HER2+ biliary tract cancer
21 November 2024
Biotechnology
Lilly and Laekna team up on novel obesity drugs
21 November 2024

Company Spotlight

A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.






Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze